Roche to present new oncology data across more than 10 cancer types at ESMO Congress 2025

Roche announced that it will present more than 30 abstracts across more than 10 cancer types at the European Society for Medical Oncology (ESMO) Congress 2025, held 17-21 October 2025 in Berlin, Germany. The data underscore Roche’s commitment to deliver transformative medicines for some of the most challenging cancer types, including breast cancers, lung cancers, gastrointestinal and genitourinary cancers.

Key presentations include:

• Giredestrant: Primary results from the phase III evERA Breast Cancer study, the first positive head-to-head phase III trial investigating a selective oestrogen receptor (ER) degrader-containing regimen versus a standard of care combination in the post-cyclin-dependent kinase inhibitor setting for people with ER-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.^1,2 The study met both co-primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival in both the intention-to-treat and ESR1-mutated populations.³ Data will be presented as a late-breaking oral abstract.
• Tecentriq: Results from the IMvigor011 trial, the first global phase III study pioneering a circulating tumour DNA (ctDNA)-guided approach to post-surgery treatment in muscle-invasive bladder cancer (MIBC).⁴ Topline results show that people who had detectable ctDNA and were treated with Tecentriq® (atezolizumab) had statistically significant and clinically meaningful improvements in disease-free survival (DFS) and overall survival (OS).⁵ Data will be presented as part of the Presidential Symposium.
• Alecensa: Final OS data from the pivotal ALEX study of Alecensa® (alectinib).⁶ Alecensa is an established first-line treatment and a standard of care for people with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).^7-9 Data will be presented as a late-breaking oral abstract and published simultaneously in the Annals of Oncology.
• Alecensa: Updated results from the phase III ALINA study, reinforcing the role of adjuvant Alecensa as the standard of care for patients with resected ALK-positive NSCLC.¹⁰ After a median follow-up of approximately four years, Alecensa DFS data compared with chemotherapy will be presented.¹⁰

View an overview of key presentations featuring Roche medicines HERE.